2023 half year results and business update
Category: TG4001
Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication
Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
Transgene immunological data demonstrating that TG4001 can induce T-cell responses
Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
TRANSGENE R&D DAY
First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
20210624 Transgene TG4001.12 FPI EN
Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
20210310 Transgene TG4001 randomized Phase II EN
Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication
Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
20201203 – TG4001 mini oral prez ESMO IO EN
